Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou Sells 4,000 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 4,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $48.48 on Wednesday. The business’s fifty day moving average is $41.53 and its 200-day moving average is $43.19. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88. The company has a market cap of $2.37 billion, a P/E ratio of 16.78, a price-to-earnings-growth ratio of 0.75 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AMPH shares. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler decreased their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $63.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC lifted its stake in shares of Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after purchasing an additional 223 shares during the period. Bridge City Capital LLC lifted its stake in shares of Amphastar Pharmaceuticals by 0.8% in the 1st quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock valued at $1,527,000 after purchasing an additional 275 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 2.5% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock valued at $452,000 after purchasing an additional 275 shares during the period. Blue Trust Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after purchasing an additional 309 shares during the period. Finally, Nations Financial Group Inc. IA ADV raised its stake in Amphastar Pharmaceuticals by 2.7% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock worth $655,000 after buying an additional 399 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.